MedTrace Logo

Intensive vs. Standard Blood Pressure Control in Primary Aldosteronism

NCT07673445 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3830

Last updated 2026-06-29

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether an intensive blood pressure control strategy (systolic blood pressure target \<120 mmHg) is more effective than a standard strategy (systolic blood pressure target \<140 mmHg) in reducing the risk of cardiovascular events in patients with primary aldosteronism.

The main question it aims to answer is: Does the intensive blood pressure control strategy reduce the risk of composite cardiovascular events more than the standard strategy in patients with primary aldosteronism? The study employs a randomized design, allocating participants in a 1:1 ratio to either the Intensive Treatment Group or the Standard Treatment Group. Researchers will compare the differences in cardiovascular outcomes and safety profiles between the two groups over a planned follow-up period of 6 to 10 years.

Participants will:

Undergo randomization and adhere to the assigned blood pressure management protocol.

Attend regular follow-up visits for blood pressure measurement, laboratory tests, questionnaires, etc.

Report any adverse events or changes in health status.

Conditions

  • Primary Aldosteronism

Interventions

DRUG

Intensive BP control

Adjusting antihypertensive medications keeps the patient's systolic blood pressure controlled at below 120 mmHg.

DRUG

Standard BP control

Adjusting antihypertensive medications keeps the patient's systolic blood pressure controlled between 120 and 140 mmHg.

Sponsors & Collaborators

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Chongqing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2036-12-31
Completion
2036-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673445 on ClinicalTrials.gov